United States

Newsroom Careers Investor Relations

s For Eye Care Professionals

Text size A- A+

Our Products Vision and Age Your Eye Concerns Our Company Search...

Contact Us

Home > Our Company > Investor Relations

Investor Relations

Like 5 Tweet 0

Valeant Pharmaceuticals International, Inc., (NYSE: VRX) (TSX: VRX) completed its acquisition of Bausch + Lomb on August 5, 2013. Bausch + Lomb will retain its name and become a division of Valeant. Valeant's existing ophthalmology businesses will be integrated into the Bausch + Lomb division, creating a global eye health platform with estimated pro forma 2013 net revenue of more than \$3.5 billion. For Investor Relations information on Valeant, click here.



Vision and Eye Health Vision and Age	Products Contact Lenses	Customer Support Contact Us	Legal Legal Notice	Newsroom Careers
Eye Infections & Irritations	Contact Lens Care	Customer policies and forms	Privacy Policy	Investor Relations
Diseases and Disorders	Dry Eye Products	Rebate Center	Safety Data Sheets (SDS)	Grants & Contributions
Find a Doctor	Allergy/Redness Relief	Worldwide Locations		
PDF Eye Exam Check List	Rx Pharmaceutical			
	Eye Vitamins			
	Surgical Products			
	Vision Accessories			

© 2015 Bausch & Lomb Incorporated.

All information and materials on this site pertain to the U.S. only, unless otherwise indicated.

